NCT05866055View on ClinicalTrials.gov

A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

April 4, 2024

Study Completion Date

April 4, 2024

Conditions
Pain
Interventions
DRUG

VX-973

Suspension for oral administration.

DRUG

Placebo

Suspension for oral administration.

DRUG

Midazolam

Syrup for oral administration.

Trial Locations (1)

Unknown

PAREXEL International, Harrow

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT05866055 - A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults | Biotech Hunter | Biotech Hunter